Author:
Kroon Maurice A. G. M.,Berbee Jacqueline K.,Majait Soumia,Swart Eleonora L.,van Tellingen Olaf,van Laarhoven Hanneke W. M.,Kemper E. Marleen
Abstract
IntroductionThe spice curcumin and its metabolites are widely used by cancer patients but have not shown proven health benefits in clinical studies, likely due to low plasma concentrations after oral intake. However, public interest in curcumin continues to grow, and companies claim enhanced absorption in their formulations. This study aims to determine if daily oral intake of curcumin leads to sufficient plasma concentrations for health effects. The study was registered in the Dutch Clinical Trial Register with ID NL5931.MethodsWe used a validated HPLC-MS/MS method to measure curcumin and its metabolites in 47 individuals using their own curcumin formulations. Questionnaires assessed other supplement and medication use. Plasma samples were collected before and 1.5 h after intake, analyzing curcumin and metabolite levels with and without β-glucuronidase pretreatment to measure conjugated and unconjugated forms.ResultsPlasma concentrations of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin, ranged between 1.0 and 18.6 ng/mL. Adding β-glucuronidase resulted in an increase of unconjugated curcumin plasma levels to 25.4 ng/mL; however still significantly below (1000-fold) a plasma concentration that is expected to have a beneficial health effect. The use of adjuvants like piperine did not result in higher curcumin plasma concentrations.DiscussionOur study shows that using oral curcumin supplements still does not result in therapeutic plasma levels. Health care practitioners need to be critical toward the claimed beneficial systemic health effects of current curcumin supplement use by their patients.Clinical Trial Registrationhttps://onderzoekmetmensen.nl/en/trial/25480, NL5931.
Subject
Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Food Science
Reference36 articles.
1. Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease;Chen;Neural Regen Res,2018
2. Molecular mechanisms underlying curcumin-mediated therapeutic effects in type 2 diabetes and Cancer;Wojcik;Oxidative Med Cell Longev,2018
3. Role of curcumin in disease prevention and treatment;Rahmani;Adv Biomed Res,2018
4. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis;Li;Cancer,2005
5. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model;Mach;Anticancer Res,2009